The abstract is read at the publisher; the summary is JClub's.
Complement-targeted therapeutics are poised to expand beyond antibody-driven disorders, with a growing pipeline aimed at inhibiting proximal or distal complement components in autoimmune and possibly degenerative neurological diseases.
- Why it matters: Complement misregulation can contribute to infectious vulnerability and to autoimmune neurological processes by impairing clearance of altered, damaged, or senescent cells.
- What they did: This Review synthesizes complement biology in central and peripheral nervous system and muscle disease, and discusses effects, merits, risks, and challenges of marketed drugs and biologic agents in ongoing phase I–III trials.
- The result: The emerging and clinical-trial complement inhibitors may broaden complement-focused treatment options for conditions such as multiple sclerosis and possibly neurodegenerative diseases including Alzheimer disease and amyotrophic lateral sclerosis.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.